← Back to Search
Current Strategies For The Delivery Of Therapeutic Proteins And Enzymes To Treat Brain Disorders.
J. Duskey, D. Belletti, F. Pederzoli, M. A. Vandelli, F. Forni, B. Ruozi, G. Tosi
Published 2017 · Medicine
Download PDFAnalyze on Scholarcy
Brain diseases and injuries are growing to be one of the most deadly and costly medical conditions in the world. Unfortunately, current treatments are incapable of ameliorating the symptoms let alone curing the diseases. Many brain diseases have been linked to a loss of function in a protein or enzyme, increasing research for improving their delivery. This is no easy task due to the delicate nature of proteins and enzymes in biological conditions, as well as the many barriers that exist in the body ranging from those in circulation to the more specific barriers to enter the brain. Several main techniques are being used (physical delivery, protein/enzyme conjugates, and nanoparticle delivery) to overcome these barriers and create new therapeutics. This review will cover recently published data and highlights the benefits and deficits of possible new protein or enzyme therapeutics for brain diseases.
This paper references
RTB Lectin: a novel receptor-independent delivery system for lysosomal enzyme replacement therapies
W. Acosta (2015)
Low‐dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA
B. King (2016)
A Neuroprotective Brain-penetrating Endopeptidase Fusion Protein Ameliorates Alzheimer Disease Pathology and Restores Neurogenesis*
B. Spencer (2014)
Intrathecal delivery of protein therapeutics to the brain: a critical reassessment.
P. Calias (2014)
Targeted Polymeric Nanoparticles for Brain Delivery of High Molecular Weight Molecules in Lysosomal Storage Disorders
Marika Salvalaio (2016)
Angiopep-2-Mediated Delivery of Human Manganese Superoxide Dismutase in Brain Endothelial Cells and its Protective Effect Against Oxidative Stress
Warawan Eiamphungporn (2014)
Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice.
H. Beard (2015)
Microbubbles in ultrasound-triggered drug and gene delivery.
S. Hernot (2008)
Diffusion of macromolecules in the brain: implications for drug delivery.
Daniel J. Wolak (2013)
The introduction of enzymes into cells by means of liposomes.
M. Finkelstein (1978)
Carbon nanospheres mediated delivery of nuclear matrix protein SMAR1 to direct experimental autoimmune encephalomyelitis in mice
S V Chemmannur (2016)
Challenges in drug delivery to the brain: nature is against us.
S. Krol (2012)
Therapeutic strategies to improve drug delivery across the blood-brain barrier.
T. Azad (2015)
A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics.
Stephanie D. Steichen (2013)
Dynamic in vitro modeling of the blood–brain barrier: a novel tool for studies of drug delivery to the brain
Damir Janigro (1999)
The N-terminal region of myelin basic protein reduces fibrillar amyloid-β deposition in Tg-5xFAD mice
Ming-Hsuan Ou-Yang (2015)
Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model.
Eun-joo Park (2012)
Effective intravenous therapy for neurodegenerative disease with a therapeutic enzyme and a peptide that mediates delivery to the brain.
Yu Meng (2014)
Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases
R. Gabathuler (2010)
Polymeric nanoparticles for drug delivery to the central nervous system.
T. Patel (2012)
Clathrin-Mediated Endocytosis Is Impaired in Type A–B Niemann–Pick Disease Model Cells and Can Be Restored by ICAM-1-Mediated Enzyme Replacement
J. Rappaport (2014)
A peptide-linked recombinant glucocerebrosidase for targeted neuronal delivery: Design, production, and assessment.
Paul A Gramlich (2016)
From gut to brain: bioencapsulated therapeutic protein reduces amyloid load upon oral delivery.
I. Mäger (2014)
Intrathecal enzyme replacement therapy improves motor function and survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosis.
J. Lu (2015)
Active Targeted Macrophage-mediated Delivery of Catalase to Affected Brain Regions in Models of Parkinson's Disease.
Y. Zhao (2011)
Nanoscale drug delivery systems and the blood–brain barrier
R. Alyautdin (2014)
Can dendrimer based nanoparticles fight neurodegenerative diseases? Current situation versus other established approaches
S. Mignani (2017)
Toward an optimal blood-brain barrier shuttle by synthesis and evaluation of peptide libraries.
Morteza Malakoutikhah (2008)
New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders.
S. Muro (2010)
Current strategies for targeted delivery of bio-active drug molecules in the treatment of brain tumor
Tarun Garg (2015)
ESCRT-mediated Uptake and Degradation of Brain-targeted α-synuclein Single Chain Antibody Attenuates Neuronal Degeneration In Vivo
B. Spencer (2014)
BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS.
H. Peluffo (2015)
Imaging approach to mechanistic study of nanoparticle interactions with the blood-brain barrier.
M. Bramini (2014)
Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections
R. Nau (2010)
Modern methods for delivery of drugs across the blood-brain barrier.
Y. Chen (2012)
Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies
Y. J. Y. Zuchero (2016)
Nanoparticles for Targeted Delivery of Antioxidant Enzymes to the Brain after Cerebral Ischemia and Reperfusion Injury
Xiang Yun (2013)
The impact of traumatic brain injuries: a global perspective.
A. Hyder (2007)
Rational engineering of single-chain polypeptides into protein-only, BBB-targeted nanoparticles.
N. Serna (2016)
Transport of drugs across the blood-brain barrier by nanoparticles.
Stefanie Wohlfart (2012)
Passive immunization targeting pathological phospho‐tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain
A. Boutajangout (2011)
Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease)
M. Katz (2014)
Comparison of Five Peptide Vectors for Improved Brain Delivery of the Lysosomal Enzyme Arylsulfatase A
A. Böckenhoff (2014)
Blood-brain barrier shuttle peptides: an emerging paradigm for brain delivery.
Benjamí Oller-Salvia (2016)
Insulin Receptor Antibody–Sulfamidase Fusion Protein Penetrates the Primate Blood–Brain Barrier and Reduces Glycosoaminoglycans in Sanfilippo Type A Cells
R. Boado (2014)
Targeted Delivery of GDNF through the Blood–Brain Barrier by MRI-Guided Focused Ultrasound
F. Wang (2012)
High-dose enzyme replacement therapy in murine Hurler syndrome.
L. Ou (2014)
Exosomes as drug delivery vehicles for Parkinson's disease therapy.
M. Haney (2015)
Augmentation of cardiac protein delivery using ultrasound targeted microbubble destruction.
R. Bekeredjian (2005)
Current approaches to enhance CNS delivery of drugs across the brain barriers
C. Lu (2014)
Tissue inhibitor of matrix metalloproteinases-1 loaded poly(lactic-co-glycolic acid) nanoparticles for delivery across the blood–brain barrier
M. Chaturvedi (2014)
In vitro models of the blood-brain barrier for the study of drug delivery to the brain.
I. Wilhelm (2014)
Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB
Shih-hsin Kan (2014)
Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect
H. Nehoff (2014)
Enzyme delivery using the 30Kc19 protein and human serum albumin nanoparticles.
Hong Jai Lee (2014)
Epidemiology of mild traumatic brain injury and neurodegenerative disease
Raquel C Gardner (2015)
Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer's disease.
M. Rotman (2015)
Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies
S. Mitragotri (2014)
Biocompatibility of a coacervate-based controlled release system for protein delivery to the injured spinal cord.
Britta Rauck (2015)
Delivery of an active lysosomal enzyme using GNeosomes.
K. Hamill (2016)
Nanoparticle-siRNA: A potential cancer therapy?
Samuel Wang Sherng Young (2016)
A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy
B. Spencer (2015)
Pathways for Small Molecule Delivery to the Central Nervous System Across the Blood-Brain Barrier
John L. Mikitsh (2014)
Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging
Sonu Bhaskar (2009)
Biodegradable double-targeted PTX-mPEG-PLGA nanoparticles for ultrasound contrast enhanced imaging and antitumor therapy in vitro
J. Ma (2016)
A&bgr;-Degrading Enzymes: Potential for Treatment of Alzheimer Disease
J. S. Miners (2011)
Progress and problems in the application of focused ultrasound for blood-brain barrier disruption.
N. Vykhodtseva (2008)
Drug Delivery Systems, CNS Protection, and the Blood Brain Barrier
R. Upadhyay (2014)
Drug delivery to the central nervous system by polymeric nanoparticles: what do we know?
J. Kreuter (2014)
Nose-to-brain delivery of macromolecules mediated by cell-penetrating peptides
Tingting Lin (2016)
Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid.
P. Dickson (2007)
Intranasal delivery of biologics to the central nervous system.
Jeffrey J Lochhead (2012)
Healing sound: the use of ultrasound in drug delivery and other therapeutic applications
S. Mitragotri (2005)
Leptin therapy improves insulin-deficient type 1 diabetes by CNS-dependent mechanisms in mice
Teppei Fujikawa (2010)
In vivo protein transduction: delivery of a biologically active protein into the mouse.
S. Schwarze (1999)
A novel dual-targeted ultrasound contrast agent provides improvement of gene delivery efficiency in vitro
Jinfeng Xu (2015)
Targeted delivery of protein and gene medicines through the blood–brain barrier
W. Pardridge (2015)
CNS Penetration of Intrathecal-Lumbar Idursulfase in the Monkey, Dog and Mouse: Implications for Neurological Outcomes of Lysosomal Storage Disorder
P. Calias (2012)
Nanopartículas poliméricas de administración intranasal para la liberación de activos en el sistema nervioso central
Mª del Pilar García Corvillo (2016)
Exosomes in Parkinson’s Disease
Xiaoqing Wu (2016)
Smuggling Drugs into the Brain: An Overview of Ligands Targeting Transcytosis for Drug Delivery across the Blood–Brain Barrier
Julia V. Georgieva (2014)
Drug delivery to the central nervous system: a review.
A. Misra (2003)
Delivery of therapeutic protein for prevention of neurodegenerative changes: Comparison of different CSF-delivery methods
N. Marshall (2015)
Ultrasound-mediated drug delivery to the brain: principles, progress and prospects.
A. Dasgupta (2016)
Nanoparticles for brain-specific drug and genetic material delivery, imaging and diagnosis.
I. Posadas (2016)
In situ brain perfusion technique.
Q. Smith (2003)
GDNF-Transfected Macrophages Produce Potent Neuroprotective Effects in Parkinson's Disease Mouse Model
Y. Zhao (2014)
Polymeric nanoparticles for the drug delivery to the central nervous system
G. Tosi (2008)
Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis.
Brian R Vuillemenot (2015)
Rapid intranasal delivery of chloramphenicol acetyltransferase in the active form to different brain regions as a model for enzyme therapy in the CNS
Abhilash P. Appu (2016)
Delivery of therapeutic agents through intracerebroventricular (ICV) and intravenous (IV) injection in mice.
Jacqueline J. Glascock (2011)
dNP2 is a blood–brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitis
Sangho Lim (2015)
Principles of nanoparticle design for overcoming biological barriers to drug delivery
E. Blanco (2015)
Oral delivery of bioencapsulated proteins across blood-brain and blood-retinal barriers.
Neha Kohli (2014)
Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier.
S. Krol (2013)
PLGA nanoparticles prepared by nano-emulsion templating using low-energy methods as efficient nanocarriers for drug delivery across the blood-brain barrier.
C. Fornaguera (2015)
Bispecific antibodies for delivery into the brain.
Ryan J Watts (2013)
‘À la Carte’ Peptide Shuttles: Tools to Increase Their Passage across the Blood–Brain Barrier
Morteza Malakoutikhah (2014)
Protein nanoparticles for intracellular delivery of therapeutic enzymes.
L. H. Estrada (2014)
Neurological consequences of traumatic brain injuries in sports
H. Ling (2015)
The “fate” of polymeric and lipid nanoparticles for brain delivery and targeting: Strategies and mechanism of blood–brain barrier crossing and trafficking into the central nervous system
G. Tosi (2016)
Synthetic fusion protein design and applications.
K. Yu (2015)
Nanoparticle Ligand Presentation for Targeting Solid Tumors
J. Duskey (2014)
Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain
R. E. Cannon (2012)
Intranasal delivery of bFGF with nanoliposomes enhances in vivo neuroprotection and neural injury recovery in a rodent stroke model.
Yingzheng Zhao (2016)
Brain delivery of proteins via their fatty acid and block copolymer modifications
X. Yi (2013)
Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome.
Y. B. Sohn (2015)
A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA
N. C. Sorrentino (2013)
Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis.
Brian R Vuillemenot (2011)
Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines
A. Mahapatro (2011)
Dual-Porosity Hollow Nanoparticles for the Immunoprotection and Delivery of Nonhuman Enzymes
Inanc Ortac (2014)
Nanotechnological advances for the delivery of CNS therapeutics.
H. L. Wong (2012)
Agile delivery of protein therapeutics to CNS.
X. Yi (2014)
This paper is referenced by
Novel peptide-conjugated nanomedicines for brain targeting: in vivo evidences.
J. Duskey (2020)
Enzyme Stability in Nanoparticle Preparations Part 1: Bovine Serum Albumin Improves Enzyme Function
J. Duskey (2020)
Nanoparticles as carriers for drug delivery of macromolecules across the blood-brain barrier
G. Tosi (2019)
The Advances of Biomacromolecule-based Nanomedicine in Brain Disease
Yuhua Weng (2019)
Theranostic Strategy of Focused Ultrasound Induced Blood-Brain Barrier Opening for CNS Disease Treatment
Ko-Ting Chen (2019)
From Animal Poisons and Venoms to Medicines: Achievements, Challenges and Perspectives in Drug Discovery
Karla C F Bordon (2020)
Lafora disease — from pathogenesis to treatment strategies
Felix Nitschke (2018)
Investigating Novel Syntheses of a Series of Unique Hybrid PLGA-Chitosan Polymers for Potential Therapeutic Delivery Applications
J. Duskey (2020)
Synthesis, Characterization, and In Vitro Studies of an Reactive Oxygen Species (ROS)-Responsive Methoxy Polyethylene Glycol-Thioketal-Melphalan Prodrug for Glioblastoma Treatment
Natalia Oddone (2020)
Drug delivery across the blood-brain barrier: recent advances in the use of nanocarriers.
J. Mulvihill (2020)